Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run ...

Moderna (MRNA) has an average rating of hold and mean price target of $118.42, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks ...

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...

Moderna MRNA shares are set to join the Nasdaq-100 Index on Oct. 9, marking another milestone for the biotech after its sharp ...

Arbutus Biopharma is a Buy, leveraging a $179.1M Moderna settlement and a 46M share buyback to enhance per-share value. Click for more on ABUS stock.

Shares of Novavax Inc (NASDAQ:NVAX) and Moderna Inc (NASDAQ:MRNA) declined on Wednesday after both companies rose in the previous session following reports of a suspected pneumonic plague case in ...

Moderna stock rallied by triple digits on Aug. 19 with positive news for its cancer vaccine. Is mRNA ready to return to the ...

Moderna, Inc. (NASDAQ:MRNA) traded at around $196 on October 7, up 4.81% on the day and 571.42% higher over twelve months.

Australia’s leading science agency has teamed up with a pharmaceutical giant to help prevent future biosecurity threats. A five-year partnership has been signed between the CSIRO and Moderna for a ...

In the recent earnings report, Moderna reiterated its forecast for as much as 10% revenue growth in the current year thanks ...

The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.

Moderna stock has rallied more than 200% since August, following positive Phase 3 trial results for a melanoma vaccine.